NCT06409819View on ClinicalTrials.gov

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

March 1, 2027

Conditions
Urinary Tract Infection, Recurrent
Interventions
DRUG

phage therapy

phage therapy will consist of a combination of three lytic phages that are active against the participant's E. coli isolates and will be administered intravenously twice daily for 7 days.

DRUG

control

Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.

Trial Locations (1)

92037

RECRUITING

University of California, San Diego, La Jolla

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of California, San Diego

OTHER

NCT06409819 - Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter